RU2014117294A - 4,6-DI (3,12-DIAZA-6,9-DIAZONIADISPIRO [5.2.5.2] HEXADECAN-1-IL) -2-METHYL-5-NITROPYRIMIDINE TETRACHLORIDE DIHYDROCHLORIDE HEXAHYDRATE FOR THE TREATMENT OF CHEMISE - Google Patents

4,6-DI (3,12-DIAZA-6,9-DIAZONIADISPIRO [5.2.5.2] HEXADECAN-1-IL) -2-METHYL-5-NITROPYRIMIDINE TETRACHLORIDE DIHYDROCHLORIDE HEXAHYDRATE FOR THE TREATMENT OF CHEMISE Download PDF

Info

Publication number
RU2014117294A
RU2014117294A RU2014117294/15A RU2014117294A RU2014117294A RU 2014117294 A RU2014117294 A RU 2014117294A RU 2014117294/15 A RU2014117294/15 A RU 2014117294/15A RU 2014117294 A RU2014117294 A RU 2014117294A RU 2014117294 A RU2014117294 A RU 2014117294A
Authority
RU
Russia
Prior art keywords
pharmaceutical composition
diazoniadispiro
hexadecan
nitropyrimidine
diaza
Prior art date
Application number
RU2014117294/15A
Other languages
Russian (ru)
Other versions
RU2573977C2 (en
RU2573977C9 (en
Inventor
Вадим Альбертович Макаров
Наталья Сергеевна Монахова
Ольга Борисовна Рябова
Original Assignee
Общество с ограниченной ответстсвенностью "НИАРМЕДИК ПЛЮС"
Федеральное государственное бюджетное учреждение науки Институт биохимии им. А.Н. Баха Российской академии наук
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Общество с ограниченной ответстсвенностью "НИАРМЕДИК ПЛЮС", Федеральное государственное бюджетное учреждение науки Институт биохимии им. А.Н. Баха Российской академии наук filed Critical Общество с ограниченной ответстсвенностью "НИАРМЕДИК ПЛЮС"
Priority to RU2014117294/15A priority Critical patent/RU2573977C9/en
Priority to PCT/RU2015/000281 priority patent/WO2015167368A1/en
Publication of RU2014117294A publication Critical patent/RU2014117294A/en
Publication of RU2573977C2 publication Critical patent/RU2573977C2/en
Application granted granted Critical
Publication of RU2573977C9 publication Critical patent/RU2573977C9/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

1. Фармацевтическая композиция для лечения герпес вирусной инфекции в виде крема, содержащая в качестве активного вещества 4,6-ди(3,12-диаза-6,9-диазониадиспиро[5.2.5.2] гексадекан-1-ил)-2-метил-5-нитропиримидин тетрахлорид дигидрохлорид гексагидрата от 0,5 до 10,0%.2. Фармацевтическая композиция для лечения герпесвирусной инфекции в виде геля, содержащая в качестве активного вещества 4,6-ди(3,12-диаза-6,9-диазониадиспиро[5.2.5.2] гексадекан-1-ил)-2-метил-5-нитропиримидин тетрахлорид дигидрохлорид гексагидрата от 0,5 до 10,0%.3. Применение фармацевтической композиции по п. 1, согласно которому крем обладает противогерпесной активностью в отношении штаммов ВПГ-1 и ВПГ-2, в том числе резистентных к существующим в настоящее время лекарственным препаратам.4. Способ лечения или предупреждения герпетической инфекции у человека или животного, включающий местное введение пациенту фармацевтической композиции по пп. 1 и/или 2 в эффективном количестве. 1. A pharmaceutical composition for the treatment of herpes viral infection in the form of a cream containing 4,6-di (3,12-diaza-6,9-diazoniadispiro [5.2.5.2] hexadecan-1-yl) -2-methyl -5-nitropyrimidine tetrachloride dihydrochloride hexahydrate from 0.5 to 10.0%. 2. A pharmaceutical composition for the treatment of herpes virus infection in the form of a gel containing 4,6-di (3,12-diaza-6,9-diazoniadispiro [5.2.5.2] hexadecan-1-yl) -2-methyl-5- as an active substance nitropyrimidine tetrachloride dihydrochloride hexahydrate from 0.5 to 10.0%. 3. The use of the pharmaceutical composition according to claim 1, wherein the cream has anti-herpes activity against HSV-1 and HSV-2 strains, including those resistant to currently existing drugs. A method for treating or preventing a herpetic infection in a human or animal, comprising topically administering to a patient a pharmaceutical composition according to claims 1 and / or 2 in an effective amount.

Claims (4)

1. Фармацевтическая композиция для лечения герпес вирусной инфекции в виде крема, содержащая в качестве активного вещества 4,6-ди(3,12-диаза-6,9-диазониадиспиро[5.2.5.2] гексадекан-1-ил)-2-метил-5-нитропиримидин тетрахлорид дигидрохлорид гексагидрата от 0,5 до 10,0%.1. Pharmaceutical composition for the treatment of herpes viral infection in the form of a cream containing 4,6-di (3,12-diaza-6,9-diazoniadispiro [5.2.5.2] hexadecan-1-yl) -2-methyl -5-nitropyrimidine tetrachloride dihydrochloride hexahydrate from 0.5 to 10.0%. 2. Фармацевтическая композиция для лечения герпесвирусной инфекции в виде геля, содержащая в качестве активного вещества 4,6-ди(3,12-диаза-6,9-диазониадиспиро[5.2.5.2] гексадекан-1-ил)-2-метил-5-нитропиримидин тетрахлорид дигидрохлорид гексагидрата от 0,5 до 10,0%.2. The pharmaceutical composition for the treatment of herpes virus infection in the form of a gel containing 4,6-di (3,12-diaza-6,9-diazoniadispiro [5.2.5.2] hexadecan-1-yl) -2-methyl- 5-nitropyrimidine tetrachloride dihydrochloride hexahydrate from 0.5 to 10.0%. 3. Применение фармацевтической композиции по п. 1, согласно которому крем обладает противогерпесной активностью в отношении штаммов ВПГ-1 и ВПГ-2, в том числе резистентных к существующим в настоящее время лекарственным препаратам.3. The use of the pharmaceutical composition according to claim 1, according to which the cream has anti-herpes activity against strains of HSV-1 and HSV-2, including those resistant to currently existing drugs. 4. Способ лечения или предупреждения герпетической инфекции у человека или животного, включающий местное введение пациенту фармацевтической композиции по пп. 1 и/или 2 в эффективном количестве. 4. A method of treating or preventing a herpetic infection in a human or animal, comprising topically administering to a patient a pharmaceutical composition according to claims. 1 and / or 2 in an effective amount.
RU2014117294/15A 2014-04-30 2014-04-30 4,6-di(3,12-diaza-6,9-diazoniadispiro[5,2,5,2]hexadecan-1-yl)-2-methyl-5-nitropyrimidine tetrachloride hydrochloride hexahydarate for treating herpetic infection, pharmaceutical composition for local application RU2573977C9 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
RU2014117294/15A RU2573977C9 (en) 2014-04-30 2014-04-30 4,6-di(3,12-diaza-6,9-diazoniadispiro[5,2,5,2]hexadecan-1-yl)-2-methyl-5-nitropyrimidine tetrachloride hydrochloride hexahydarate for treating herpetic infection, pharmaceutical composition for local application
PCT/RU2015/000281 WO2015167368A1 (en) 2014-04-30 2015-04-29 4, 6-di (3,12-diaza-6, 9-diazoniadispiro [5.2.5.2] hexandecan-1-yl) -2-methyl-5-nitropyrimidine tetrachloride dihydrochloride hexahydrate for the treatment of herpetic infection and a topical pharmaceutical composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2014117294/15A RU2573977C9 (en) 2014-04-30 2014-04-30 4,6-di(3,12-diaza-6,9-diazoniadispiro[5,2,5,2]hexadecan-1-yl)-2-methyl-5-nitropyrimidine tetrachloride hydrochloride hexahydarate for treating herpetic infection, pharmaceutical composition for local application

Publications (3)

Publication Number Publication Date
RU2014117294A true RU2014117294A (en) 2015-11-10
RU2573977C2 RU2573977C2 (en) 2016-01-27
RU2573977C9 RU2573977C9 (en) 2016-08-27

Family

ID=53484118

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014117294/15A RU2573977C9 (en) 2014-04-30 2014-04-30 4,6-di(3,12-diaza-6,9-diazoniadispiro[5,2,5,2]hexadecan-1-yl)-2-methyl-5-nitropyrimidine tetrachloride hydrochloride hexahydarate for treating herpetic infection, pharmaceutical composition for local application

Country Status (2)

Country Link
RU (1) RU2573977C9 (en)
WO (1) WO2015167368A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2633699C2 (en) * 2015-10-20 2017-10-17 Общество С Ограниченной Ответственностью "Ниармедик Плюс" Pyrimidyl-di(diazadispiroalkane)s with antiviral activity
CN106083761A (en) * 2016-06-16 2016-11-09 盐城工学院 The preparation method of the monosubstituted piperazine compounds of a kind of N and application
RU2761950C1 (en) * 2020-12-08 2021-12-14 Федеральное государственное учреждение «Федеральный исследовательский центр «Фундаментальные основы биотехнологии» Российской академии наук» Derivatives of di(diazoniadispiro[5.2.5.2]hexadecane)-5-nitropyrimidine and their use for treatment of coronavirus infections, in particular caused by sars-cov-2 virus
CN114644636B (en) * 2022-04-20 2023-10-20 江苏恒沛药物科技有限公司 Method for preparing tofacitinib key intermediate

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4914131A (en) * 1984-03-08 1990-04-03 Dana P. Brigham Antiviral pharmaceutical preparations and methods for their use
DE19851375A1 (en) * 1998-11-07 2000-05-11 Friedrich Schiller Uni Jena Bu Use of cyclic diazadiazonia-dispiro-alkane derivatives for the treatment and prophylaxis of virus infections, especially herpes and HIV infections
DE19934585A1 (en) * 1999-07-23 2001-01-25 Rapp Horst Treatment of dermatological disorders, e.g. pruritus, herpes simplex infection, psoriasis or acne, using tosyl chloramide salt, e.g. in ointment or gel base
WO2009154201A1 (en) * 2008-06-18 2009-12-23 国立大学法人京都大学 Cell adhesion promoting agent and method of promoting cell adhesion

Also Published As

Publication number Publication date
WO2015167368A1 (en) 2015-11-05
RU2573977C2 (en) 2016-01-27
RU2573977C9 (en) 2016-08-27

Similar Documents

Publication Publication Date Title
BR112017016006A2 (en) compound, pharmaceutical composition, method of treating diseases and conditions, use of a compound and a combination, and, combination.
PH12015502539B1 (en) Cenicriviroc compositions and methods of making and using the same
EA202090258A3 (en) PYRROLO [3,2-D] PYRIMIDINE DERIVATIVES FOR TREATMENT OF VIRAL INFECTIONS AND OTHER DISEASES
PH12017500479A1 (en) Liquid inhalation formulation comprising prl554
EA202090662A2 (en) PYRROLO [3,2-d] PYRIMIDINE DERIVATIVES FOR TREATMENT OF VIRAL INFECTIONS AND OTHER DISEASES
BR112015020787A2 (en) quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
MY201105A (en) Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
MX2022003072A (en) Use of pridopidine for treating functional decline.
MX2014004814A (en) Compounds and methods for enhancing innate immune responses.
EA201591541A1 (en) BETA SECRETASE INHIBITORS 1 (BACE 1)
WO2015187998A3 (en) Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy
RU2014117294A (en) 4,6-DI (3,12-DIAZA-6,9-DIAZONIADISPIRO [5.2.5.2] HEXADECAN-1-IL) -2-METHYL-5-NITROPYRIMIDINE TETRACHLORIDE DIHYDROCHLORIDE HEXAHYDRATE FOR THE TREATMENT OF CHEMISE
EA201492097A1 (en) 5-AMINO [1,4] TIAZINS AS BETA SECRETASE INHIBITORS 1
EA201890643A1 (en) MEDICINAL PRODUCTS AND MEDICAL PRODUCTS CONTAINING ACETHYLSALICYL ACID FOR THE TREATMENT OF SKIN INFECTIONS CAUSED BY THE HUMAN PAPILLOMO VIRUS
WO2014164285A3 (en) Use of levocetirizine and montelukast in the treatment of vasculitis
BR112017001160A2 (en) [1,2,4] triazole [4,3-b] pyridazine for use in the treatment of proliferative diseases
PH12015502128A1 (en) Novel dosing regimens of celgosivir for the treatment of dengue
BR112017016278A2 (en) Prevention and/or the medical treatment agent of immunopathy
WO2016159582A3 (en) Composition for innate immunity enhancement and antiviral activity containing schizonepeta tenuifolia extract as active ingredient
JP2015044878A5 (en)
WO2016159583A3 (en) Composition for innate immunity enhancement and antiviral activity containing hovenia dulcis extract as active ingredient
WO2014140680A8 (en) Dosing regimen for use of celgosivir as an antiviral therapeutic for dengue virus infection
MX2020001356A (en) Pharmaceutical compositions.
WO2018084817A3 (en) A new form of active agent
BR112017017229A2 (en) compound, compound for medical use or in the preparation of a medicament and pharmaceutical composition

Legal Events

Date Code Title Description
PD4A Correction of name of patent owner
TH4A Reissue of patent specification
TK4A Correction to the publication in the bulletin (patent)

Free format text: AMENDMENT TO CHAPTER -FG4A- IN JOURNAL: 3-2016 FOR TAG: (73)

TK4A Correction to the publication in the bulletin (patent)

Free format text: AMENDMENT TO CHAPTER -PD4A - IN JOURNAL: 22-2016 FOR TAG: (73)

PC41 Official registration of the transfer of exclusive right

Effective date: 20170731